Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / HSP90a

HSP90a

Basics

Aliases:
This biomarker is also known as:
  • heat shock 86 kDa,
  • Renal carcinoma antigen NY-REN-38,
  • HSPN,
  • HSP90A,
  • heat shock protein 90kDa alpha (cytosolic), class A member 1,
  • heat shock protein HSP 90-alpha,
  • FLJ31884,
  • HSPC1,
  • HSP89A,
  • Hsp90,
  • HSPCAL1,
  • heat shock 90kD protein 1, alpha,
  • HSP90AA1,
  • HSPCA,
  • HSP86,
  • heat shock 90kD protein 1, alpha-like 4,
  • HSP 86,
  • heat shock 90kDa protein 1, alpha,
  • LAP2,
  • HSPCAL4,
  • HSP90N,
  • renal carcinoma antigen NY-REN-38,
  • Heat shock 86 kDa,
  • heat shock 90kD protein, alpha-like 4,
  • Hsp89,

View in BioMuta

Description…

The HSP90AA1 protein, also known as HSP90a, is a molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved in cell cycle control and signal transduction. HSP90AA1 is a homodimer that assists in the proper folding of specific target proteins by use of an ATPase activity that is modulated by co-chaperones. Two transcript variants encoding different isoforms have been found for this gene.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: HSP90AA1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Overview

HSP90a is important for the stability of and function of a wide range of oncoproteins and has been been identified in serum and lung cancer tissue or cell culture as a candidate lung cancer biomarker.

Performance Comment

It has been shown that levels of HSP90a were elevated in lung cancer patients, and that the levels of HSP90a increased along with the clinical state of the NSCLC. HSP90a has been shown to participate in the metastasis of lung cancer. HSP90A is also a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.